Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication

Stroke

Volumn 43, Issue 6, 2012, Pages 1647-1653

  Elali, Ayman ^a   Urrutia, Andrés ^b   Rubio Araiz, Ana ^b   Hernandez Jimenez, MacArena ^b   Colado, Maria I ^b   Doeppner, Thorsten R ^a   Hermann, Dirk M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

apolipoprotein E receptor 2; blood brain barrier; c Jun N terminal kinase 1 2; drug abuse; endothelium; multidrug resistance; neuropathology; signal transduction; tight junction

Indexed keywords

ABC TRANSPORTER; ABCC1 PROTEIN; ADENOSINE TRIPHOSPHATE; APOLIPOPROTEIN E2; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; METHAMPHETAMINE; MITOGEN ACTIVATED PROTEIN KINASE 9; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN C JUN; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL TISSUE; ARTICLE; BRAIN BLOOD VESSEL; BRAIN CAPILLARY; BRAIN HEMORRHAGE; BRAIN PROTECTION; BRAIN TISSUE; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG DEPENDENCE; ENZYME ACTIVATION; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; INTOXICATION; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; STROKE; THROMBOEMBOLISM; TIGHT JUNCTION; WESTERN BLOTTING;

ANIMALS; APOLIPOPROTEINS E; BRAIN ISCHEMIA; CAPILLARIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLUM; CEREBROVASCULAR CIRCULATION; HUMANS; IMINES; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MALE; MAP KINASE SIGNALING SYSTEM; METHAMPHETAMINE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SUBSTANCE-RELATED DISORDERS; TIGHT JUNCTIONS;

EID: 84861637607     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.648923     Document Type: Article

References (32)

1. Sandoval V, Hanson GR, Fleckenstein AE. Methamphetamine decreases mouse striatal dopamine transporter activity: roles of hyperthermia and dopamine. Eur J Pharmacol. 2000;409:265-271.
2. Sugimoto K, Okamura K, Tanaka H, Takashima S, Ochi H, Yamamoto T, et al. Methamphetamine directly accelerates beating rate in cardiomyocytes by increasing Ca(2 ) entry via L-type Ca(2 ) channel. Biochem Biophys Res Commun. 2009;390:1214-1220.
3. Xie T, McCann UD, Kim S, Yuan J, Ricaurte GA. Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity. J Neurosci. 2000;20:7838-7845.
4. Kuhn DM, Geddes TJ. Molecular footprints of neurotoxic amphetamine action. Ann N Y Acad Sci. 2000;914:92-103.
5. Cadet JL, Jayanthi S, Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J. 2003;17:1775-1788.
6. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, et al. Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci. 2003;28:5756-5761.
7. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem. 2006;96:706-718.
8. Kiyatkin EA, Brown PL, Sharma HS. Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci. 2007;26:1242-1253.
9. Martins T, Baptista S, Gonçalves J, Leal E, Milhazes N, Borges F, et al. Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res. 2011;1411:28-40.
10. Ho EL, Josephson SA, Lee HS, Smith WS. Cerebrovascular complications of methamphetamine abuse. Neurocrit Care. 2009;10: 295-305.
11. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53.
12. Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005;6:591-602.
13. Hermann DM, Kilic E, Spudich A, Krämer SD, Wunderli-Allenspach H, Bassetti CL. Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol. 2006;60:489-498.
14. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Adal A, et al. Methamphetamine alters blood-brain barrier permeability via the modulation of tight junction expression: implication for HIV-1 neuropathogenesis in the context of drug abuse. Brain Res. 2008;1203: 133-148.
15. Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, et al. Methamphetamine disrupts blood-brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab. 2009;29:1933-1945.
16. Abdul Muneer PM, Alikunju S, Szlachetka AM, Murrin LC, Haorah J. Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol Neurodegener. 2011;6:23.
17. Mann H, Ladenheim B, Hirata H, Moran TH, Cadet JL. Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice. Brain Res. 1997;769:340-346.
18. Spudich A, Kilic E, Xing H, Kilic U, Rentsch KM, Wunderli-Allenspach H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006; 9:487-488.
19. Kilic E, Spudich A, Kilic U, Rentsch KM, Vig R, Matter CM, et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain. 2008;131:2679-2689.
20. ElAli A, Hermann DM. Apolipoprotein-E controls ATP-binding cassette transporters in the ischemic brain. Sci Signal. 2010;3:ra72.
21. ElAli A, Hermann DM. Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells. Brain Pathol. Published ahead of print July 18, 2011. DOI: 10.1111/j.1750-3639. 2011.00517.x.
22. Yu KC, Jiang Y, Chen W, Cooper AD. Evaluation of the components of the chylomicron remnant removal mechanism by use of the isolated perfused mouse liver. J Lipid Res. 1999;40:1899-1910.
23. Lambert MP, Wang Y, Bdeir KH, Nguyen Y, Kowalska MA, Poncz M. Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. Blood. 2009;114:2290-2298.
24. Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: cardiovascular system. Experientia. 1986;42:292-297.
25. Bell GJ, Hiley CR, Yates MS. The effect of four general anesthetic agents on the regional distribution of cardiac output in the rat. Br J Pharmacol. 1977;61:126-127.
26. Lahti A, Jalonen U, Kankaanranta H, Moilanen E. c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages. Mol Pharmacol. 2003;64:308-315.
27. Pawate S, Bhat NR. C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform. Antioxid Redox Signal. 2006;8:903-909.
28. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104:1085-1099.
29. Bowyer JF, Robinson B, Ali S, Schmued LC. Neurotoxic-related changes in tyrosine hydroxylase, microglia, myelin, and the blood-brain barrier in the caudate-putamen from acute methamphetamine exposure. Synapse. 2008;62:193-204.
30. Wang Y, Hayashi T, Chang CF, Chiang YH, Tsao LI, Su TP, Borlongan C, Lin SZ. Methamphetamine potentiates ischemia/reperfusion insults after transient middle cerebral artery ligation. Stroke. 2001;32: 775-782.
31. Polesskaya O, Silva J, Sanfilippo C, Desrosiers T, Sun A, Shen J, Feng C, Polesskiy A, Deane R, Zlokovic B, Kasischke K, Dewhurst S. Methamphetamine causes sustained depression in cerebral blood flow. Brain Res. 2011;1373:91-100.
32. Hermann DM, Bassetti CL. Implications of ATP-binding cassette transporters for brain pharmacotherapies. Trends Pharmacol Sci. 2007;28: 128-134.